F]Galacto-RGD
- Haubner Roland
- Weber Wolfgang A
- Beer Ambros J
- Vabuliene Eugenija
- Reim Daniel
- Sarbia Mario
- Becker Karl-Friedrich
- Goebel Michael
- Hein Rüdiger
- Wester Hans-Jürgen
- Kessler Horst
- Schwaiger Markus
DOIAbstract
F-labeled glycosylated αvβ3 antagonist, allowing monitoring of αvβ3 expression with positron emission tomography (PET).F]Galacto-RGD with PET enables noninvasive quantitative assessment of the αvβ3 expression pattern on tumor and endothelial cells in patients with malignant tumors.F]Galacto-RGD and PET can provide important information for planning and monitoring anti-angiogenic therapies targeting the αvβ3 integrins and can reveal the involvement and role of this integrin in metastatic and angiogenic processes in various diseases
Add to ORKG